U.S. FDA APPROVES UPDATE TO THE LABEL FOR WINREVAIR™ (SOTATERCEPT-CSRK) TO INCLUDE DATA FROM THE PHASE 3 HYPERION TRIAL EVALUATING ADULTS RECENTLY DIAGNOSED WITH PULMONARY ARTERIAL HYPERTENSION (PAH, WHO* GROUP 1 PULMONARY HYPERTENSION)

Reuters · 3d ago

Please log in to view news